Gilead Sciences Inc. (GILD)
-NasdaqGS 56.30 
1.34(2.44%) May 17, 4:00PM EDT|After Hours
:
56.55 0.25 (0.44%) May 17, 7:24PM EDT
| Prev Close: | 54.96 |
|---|
| Open: | 55.36 |
|---|
| Bid: | 56.55 x 200 |
|---|
| Ask: | 56.98 x 200 |
|---|
| 1y Target Est: | 63.88 |
|---|
| Beta: | 0.81 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 54.65 - 56.43 |
|---|
| 52wk Range: | 24.12 - 57.10 |
|---|
| Volume: | 13,909,763 |
|---|
| Avg Vol (3m): | 11,816,500 |
|---|
| Market Cap: | 85.82B |
|---|
| P/E (ttm): | 31.52 |
|---|
| EPS (ttm): | 1.79 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 3 Horrendous Health-Care Stocks This Weekat Motley Fool(Sat 8:45AM EDT)
- Final Glance: Biotechnology companiesAP(Fri, May 17)
- Staples Launches Sports & Art Photo Gallery and 2 More Heavily Traded Stocks to Followat Wall St. Cheat Sheet(Fri, May 17)
- Gilead Sciences to Present at the 2013 UBS Global Healthcare Conference on Monday, May 20Business Wire(Fri, May 17)
- Midday Glance: Biotechnology companiesAP(Fri, May 17)
- Jim Cramer: Buy Gilead Sciences, Kinder Morgan, and These 3 Solid Stocks Nowat Wall St. Cheat Sheet(Fri, May 17)
- Bypassing Biotechs and Focusing on the Overlooked Medical Device Space: An Expert Portfolio Manager Discusses His Contrarian Approach to InvestingWall Street Transcript(Fri, May 17)
- Analyst Moves: NOC, GM, GILDat Forbes(Fri, May 17)
- Early Glance: Biotechnology companiesAP(Fri, May 17)
- Cramer's Lightning Round - I've Had It With Magnum Hunter (5/16/13)at Seeking Alpha(Fri, May 17)
- 'Mad Money' Lightning Round: Magnum Hunter Blew Itat TheStreet(Fri, May 17)
- [$$] AbbVie Is Good Medicineat Barrons.com(Thu, May 16)
- Lightning Round: Starbucks, Gilead & Moreat CNBC(Thu, May 16)
- Eyeing Business Models and Practices that are Sustainable and Value-Creating in the Biotech and Pharmaceutical SectorsWall Street Transcript(Thu, May 16)
- Gilead Drug For Leukemia Shows Success In Early Trialat Investor's Business Daily(Thu, May 16)
Key Statistics
| Forward P/E (1 yr): | 19.41 |
|---|
| P/S (ttm): | 8.42 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.98 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.49 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | 1.11 |
|---|
Business Summary
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia.
View More